Tysabri and Progressive Multifocal Leukoencephalopathy: Legal Considerations for Washington Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Literacy to Occupational and Therapeutic Risk

The legacy of general health and science information dissemination has long served as a foundation for public awareness, guiding individuals through complex medical landscapes with clarity and caution. Within this tradition, the focus on therapeutic interventions and their potential long-term consequences has been paramount, particularly as treatments evolve from experimental to mainstream use. This heritage emphasizes the importance of understanding both benefits and risks, fostering an informed dialogue between patients, providers, and regulatory bodies. As this informational framework matures, it naturally extends into specialized domains where therapeutic exposure intersects with occupational and environmental health. The case of Tysabri, a biologic therapy used in certain chronic conditions, exemplifies this pivot. While clinical discussions have centered on patient outcomes, a parallel concern emerges for those in manufacturing, handling, or administration settings. Here, the risk of exposure to the active agent—and its association with progressive multifocal leukoencephalopathy—shifts from a patient-centric narrative to an occupational hazard. Workers in production facilities, laboratories, or healthcare environments may face inadvertent contact, raising questions about safety protocols, monitoring, and legal recourse. This transition from general health literacy to specific exposure scenarios underscores the need for rigorous occupational health frameworks, particularly when addressing liability and statute of limitations in jurisdictions like Washington.

Medical Evidence Linking Tysabri to Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Washington who have developed PML after Tysabri exposure, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is critical. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation often includes progressive neurological deficits such as weakness, cognitive decline, vision loss, speech difficulties, and coordination problems. Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. Early recognition is essential because Tysabri must be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Risk Factors and Mechanistic Pathways

Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cell migration into the central nervous system. This mechanism reduces inflammation in multiple sclerosis but also impairs immune surveillance, allowing JCV reactivation. Three established risk factors increase PML risk in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic link between Tysabri and PML involves impaired central nervous system immune surveillance. By blocking lymphocyte trafficking, Tysabri reduces the ability of the immune system to control JCV replication in the brain. This allows the virus to infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is compounded by prior immunosuppressant use, which may further compromise immune function. The FDA-approved labeling emphasizes that Tysabri increases the risk of PML, and healthcare professionals should monitor patients for any new sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Risk Communication

The prescribing information for Tysabri includes a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also notes that risk factors include anti-JCV antibodies, duration of therapy, and prior immunosuppressant use. Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled in this program, read the Medication Guide, understand the risks, and complete a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether the risks were adequately communicated to individual patients, particularly regarding the magnitude of PML risk and the importance of early symptom recognition.

Statute of Limitations for Tysabri Claims in Washington

For patients in Washington who have developed PML after Tysabri use, potential legal claims may involve failure to warn, inadequate risk communication, or product liability. The statute of limitations for personal injury claims in Washington is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can vary. PML typically occurs after prolonged treatment, often beyond 2 years, but cases have been reported after shorter durations. The onset of symptoms may be gradual, and diagnosis may be delayed, affecting when the injury is considered discovered. Patients should consult with a legal professional promptly to assess their specific circumstances and ensure compliance with applicable deadlines. The risk of PML increases with longer treatment duration, especially beyond 2 years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML can occur at any time during treatment. Once symptoms develop, they may progress rapidly, leading to severe disability or death. Early diagnosis and discontinuation of Tysabri are critical, but even with prompt intervention, outcomes are often poor. The latency period between initial JCV infection or reactivation and clinical PML is not precisely defined, but the presence of anti-JCV antibodies is a key risk marker. Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This underscores the importance of regular monitoring and risk stratification.

Conclusion and Next Steps

Tysabri-associated PML is a devastating complication with high morbidity and mortality. The medical evidence clearly establishes the link between Tysabri and PML, identifies risk factors, and mandates strict monitoring protocols. For affected patients in Washington, understanding the statute of limitations and seeking timely legal advice is essential. The adequacy of warnings and the timeline of harm are central to any settlement considerations. Patients should retain all medical records, including documentation of Tysabri treatment, PML diagnosis, and any communications regarding risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Washington?

In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML, this may depend on when symptoms appeared and diagnosis was confirmed. It is crucial to consult an attorney promptly to avoid missing the deadline.

What are the main risk factors for developing PML while on Tysabri?

The three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed in Tysabri patients?

Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via PCR. Early recognition is essential because Tysabri must be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.